Argus raised the firm’s price target on GE HealthCare to $110 from $80 and keeps a Buy rating on the shares. Having achieved a solid track of innovation in 2023, the company presented an upbeat outlook for 2024 on its Q4 earnings call as it intends to will focus on launching new products and solutions that incorporate AI and digital technologies, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE Healthcare (NASDAQ:GEHC) Gets Boost from New Technology
- GE Hlthcare Tech Inc put volume heavy and directionally bearish
- GE HealthCare announces FDA clearance for nCommand Lite technology
- GE HealthCare accelerates AI innovation with models powered by Nvidia
- China stimulus positive for GE HealthCare, tool companies, says Evercore ISI
